Glutathione S-Transferase in Human Endometrium: Quantitation and Interindividual Variability in Isoform Content

Barnette, K. Gary; Sarkar, Mitali; Glover, Douglas D.; Li, Ping; Boyd, C. A. R.; Lalka, David

doi:10.1159/000010073

Cited by 8 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of asthma complicating pregnancy has increased [50], and it is now estimated that it affects 8% of pregnant women [51]. Gluck investigated this disease during pregnancy, observing that asthma improves in 1/3 of cases, worsens in 1/3, and remains unchanged in the last 1/3 [49].…”

Section: Physiologic Changes Of Pregnancymentioning

confidence: 99%

Clinical Therapeutics in Pregnancy

Feghali

Mattison

2011

BioMed Research International

View full text Add to dashboard Cite

Most drugs are not tested for use during pregnancy, consequently, labeling, which may include information about fetal safety, includes nothing about dosing, efficacy, or maternal safety. Yet these are concerns of health care providers considering treatment of disease during pregnancy. Therefore, the practitioner treats the pregnant woman with the same dose recommended for use in adults (typically men) or may decide not to treat the disease at all. However, is the choice of not treating a woman during pregnancy better than dealing with the challenges which accompany treatment? This paper, which summarizes metabolic and physiologic changes induced by pregnancy, illustrates that standard adult dosing is likely to be incorrect during pregnancy.

show abstract

Section: Physiologic Changes Of Pregnancymentioning

confidence: 99%

Clinical Therapeutics in Pregnancy

Feghali

Mattison

2011

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The quinones can be deactivated by conjugation with glutathione by glutathione S-transferases (GST; ref. 21), which are expressed in the endometrium (22,23).…”

Section: Introductionmentioning

confidence: 99%

Genetic Factors in Catechol Estrogen Metabolism in Relation to the Risk of Endometrial Cancer

Doherty

Weiss

Freeman

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

2-Hydroxylated metabolites of estrogen have been shown to have antiangiogenic effects and inhibit tumor cell proliferation, whereas 4-hydroxylated metabolites have been implicated in carcinogenesis. We examined whether polymorphisms in certain genes involved in estrogen metabolism are associated with endometrial cancer risk in a populationbased case-control study with 371 cases and 420 controls. Based on previously published genotype-phenotype correlation studies, we defined variant alleles thought to increase estrogen 2-hydroxylation as presumptively low-risk (CYP1A1 m1 T6235C and m2 Ile 462 Val) and those thought to increase estrogen 4-hydroxylation as high-risk (CYP1A1 m4 Thr 461 Asn, CYP1A2 A734C, and CYP1B1 Leu 432 Val). Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using unconditional logistic regression. Carrying at least one CYP1A1 m1 or m2 variant allele was associated with a decreased risk of endometrial cancer [ORs (95% CIs), 0.64 (0.44-0.93) and 0.54 (0.30-0.99), respectively]. No strong alteration in risk was observed among women with any of the putative high-risk alleles. When CYP1A1, CYP1A2, and CYP1B1 genotypes were combined and ranked by the number of putative low-risk genotypes carried, women with four or five low-risk genotypes had a reduced risk of endometrial cancer (OR, 0.29; 95% CI, 0.15-0.56) compared with women with one or none. No appreciable alteration in risk was observed among women carrying two or three low-risk genotypes. Some of our findings are consistent with the hypothesis that increased estrogen 2-hydroxylation is associated with decreased endometrial cancer risk, but replication of these results is required before any firm conclusions can be reached.

show abstract

“…Barnette et al 17 observed the presence of GSTpi in normal and cancerous endometrium. 17 GSTpi expression was lower in cancer patients who smoked, but no relationship between grade, outcome or chemoresistance was demonstrated. In the present study, we confirmed the expression of GSTpi in established endometrial cancer cells.…”

Section: Discussionmentioning

confidence: 99%

“…16 In endometrial cancer, however, the role of GSTpi is unknown. Barnette et al 17 observed the presence of GSTpi in normal and cancerous endometrium. 17 GSTpi expression was lower in cancer patients who smoked, but no relationship between grade, outcome or chemoresistance was demonstrated.…”

Section: Studies Have Shown That Cddp Inducesmentioning

confidence: 99%

Steroid and Xenobiotic Receptor (SXR) is a Key System for the Acquisition of Cisplatin Resistance in Endometrial Cancer Cells

2003

View full text Add to dashboard Cite

A novel steroid and xenobiotic receptor (SXR) may be involved in chemoresistance, and we studied this receptor in endometrial cancer cell lines. The cisplatin (CDDP)-sensitive Ishikawa cell line and its CDDP-resistant sub-clone (ISIW+) were used. ISIW+ cells showed a much higher SXR expression. When Ishikawa cells were cultured with SXR anti-sense oligonucleotides (AS), the cells failed to pass crisis and did not gain cisplatin resistance. In an experiment using SCID mice, all AS-treated animals survived, whereas controls had 50% survival at 35 days. The present data indicate that SXR is a key system to induce, maintain and reverse a cisplatin-resistant phenotype in endometrial cancer cells.

show abstract

Glutathione S-Transferase in Human Endometrium: Quantitation and Interindividual Variability in Isoform Content

Cited by 8 publications

References 15 publications

Clinical Therapeutics in Pregnancy

Clinical Therapeutics in Pregnancy

Genetic Factors in Catechol Estrogen Metabolism in Relation to the Risk of Endometrial Cancer

Steroid and Xenobiotic Receptor (SXR) is a Key System for the Acquisition of Cisplatin Resistance in Endometrial Cancer Cells

Contact Info

Product

Resources

About